Use of Cell Therapy to Enhance Arthroscopic Knee Cartilage Surgery

NCT ID: NCT01799876

Last Updated: 2019-01-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-02-28

Study Completion Date

2017-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the potential benefit of enhancing knee surgery for cartilage injury using some of the patient's own cells, taken from fat tissue, that may be able to help cartilage to regenerate.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participation in this study will allow the surgical team to remove a small amount of fat (20 to 30 ml, or between 1 and 2 tablespoons) from just below the skin in the belly region that will be processed to remove regenerative cells, which will then inserted into the knee to the damaged cartilage. These cells may encourage healing at the surgical site, although whether or how much they encourage healing is unknown. Determining whether such improved healing occurs is the purpose of this study.

Some patients will have the fat removed and cells inserted in their knee, and other patients will not have the fat removed or cells inserted. To which group patients are assigned is determined by a random process, similar to flipping a coin. The surgery is the same in all other ways for all patients.

Participation will require attending regularly scheduled postoperative visits, having 3 MRI tests, and answering a short survey. No additional visits other beyond those normally scheduled for postsurgical care are required.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Articular Cartilage Defect Grade III or IV of the Knee

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Autologous Cell

Regenerative cells obtained from autologous fat are administered in the knee at microfracture site.

Group Type EXPERIMENTAL

Autologous Cell

Intervention Type PROCEDURE

Control

Standard arthroscopy with sham lipoplasty procedure (no fat cells harvested).

Group Type SHAM_COMPARATOR

Standard microfracture arthroscopic surgery

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Autologous Cell

Intervention Type PROCEDURE

Standard microfracture arthroscopic surgery

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects undergoing microfracture surgery for the repair of articular cartilage
* Osteochondral defect Grade III or IV
* Age 18 to 68 years
* Sufficient subcutaneous adipose tissue to yield 20-30 cc of lipoaspirate
* Written informed consent
* Ability to speak, read and write English or Spanish

Exclusion Criteria

* Inability to speak, read and write English or Spanish
* Evidence of malignant disorder/neoplasm in past 24 months
* History of basal cell carcinoma
* History of smoking and not committed to give up
* Chronic skin conditions
* Connective, metabolic or skin disease
* Evidence of active infection
* Pregnancy or lactating for female subjects
* Diabetes Type I or II
* Current steroid use
* Immunosuppressive medication
* Renal failure (creatine \> 1.8 mg/dL)
* Hepatic failure (AST, ALT \>2 times normal values; bilirubin \>2.0 mg/dL)
* Inflammatory joint diseases of the knee that indicate additional, conflating therapies
* Joint infection within the past 6 months
* Meniscal resection of greater than 50% prior to, or at time of procedure
* Uncorrected joint instability
* Joint malalignment \> 5 degrees
Minimum Eligible Age

18 Years

Maximum Eligible Age

68 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

InGeneron, Inc.

INDUSTRY

Sponsor Role collaborator

Fondren Orthopedic Group L.L.P.

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert L Burke, MD

Role: PRINCIPAL_INVESTIGATOR

Fondren Orthopedic Group L.L.P.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fondren Orthopedic Group, L.L.P.

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FOG-TOH125

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.